Trials / Recruiting
RecruitingNCT06503809
Efficacy and Safety of a Ketogenic Diet in Type 1 Diabetes
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 58 (estimated)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Despite strong evidence that tight control of blood sugar reduces the risk of diabetes complications, most people with type 1 diabetes do not achieve recommended blood sugar targets. This randomized controlled trial will test whether a very-low- carbohydrate ketogenic diet can effectively and safely improve blood sugar control in adults with type 1 diabetes.
Detailed description
A very-low-carbohydrate ketogenic diet (≤50 g carbohydrate/day) could reduce glycemic variability, total daily insulin requirement, and HbA1c in people with type 1 diabetes (T1D). Indeed, several case series and observational studies of using a ketogenic diet (KD) in people with T1D have observed such benefits. However, no randomized controlled trials (RCTs) have evaluated the efficacy of KD for \>7 days in people with T1D. In addition, there are serious concerns regarding the safety and tolerability of a KD in patients with T1D, including the potential for an increased risk of hypoglycemia, diabetic ketoacidosis, dyslipidemia, insulin resistance, decreased bone mineral density, and impaired quality of life. This study is a 12-week RCT to evaluate the clinical efficacy, metabolic function, safety, socio-behavioral impact, acceptability and potential for dissemination of an isocaloric KD compared with an American Diabetes Association-recommended control diet in adults with T1D.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Ketogenic Diet | Participants will consume a very-low-carbohydrate ketogenic diet for 12 weeks. |
| BEHAVIORAL | Standard Diet | Participants will consume an American Diabetes Association-recommended standard diet for 12 weeks. |
Timeline
- Start date
- 2024-08-12
- Primary completion
- 2030-02-28
- Completion
- 2030-03-31
- First posted
- 2024-07-16
- Last updated
- 2026-03-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06503809. Inclusion in this directory is not an endorsement.